155 related articles for article (PubMed ID: 12574398)
1. In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection.
Pincus SH; Fang H; Wilkinson RA; Marcotte TK; Robinson JE; Olson WC
J Immunol; 2003 Feb; 170(4):2236-41. PubMed ID: 12574398
[TBL] [Abstract][Full Text] [Related]
2. A modified SCID mouse model of HIV infection with utility for testing anti-HIV therapies.
Pincus SH; Fang H; Wilkinson RA; Olson WC; Marcotte TK
AIDS Res Hum Retroviruses; 2003 Oct; 19(10):901-8. PubMed ID: 14585222
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus.
Pincus SH; McClure J
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):332-6. PubMed ID: 8419938
[TBL] [Abstract][Full Text] [Related]
4. Rationale for the use of immunotoxins in the treatment of HIV-infected humans.
Van Oijen MG; Preijers FW
J Drug Target; 1998; 5(2):75-91. PubMed ID: 9588864
[TBL] [Abstract][Full Text] [Related]
5. Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice.
Sanhadji K; Grave L; Touraine JL; Leissner P; Rouzioux C; Firouzi R; Kehrli L; Tardy JC; Mehtali M
AIDS; 2000 Dec; 14(18):2813-22. PubMed ID: 11153662
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
[TBL] [Abstract][Full Text] [Related]
7. In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160.
Pincus SH; Wehrly K; Cole R; Fang H; Lewis GK; McClure J; Conley AJ; Wahren B; Posner MR; Notkins AL; Tilley SA; Pinter A; Eiden L; Teintze M; Dorward D; Tolstikov VV
AIDS Res Hum Retroviruses; 1996 Jul; 12(11):1041-51. PubMed ID: 8827220
[TBL] [Abstract][Full Text] [Related]
8. Selective killing of HIV-infected cells by anti-gp120 immunotoxins.
Matsushita S; Koito A; Maeda Y; Hattori T; Takatsuki K
AIDS Res Hum Retroviruses; 1990 Feb; 6(2):193-203. PubMed ID: 2328157
[TBL] [Abstract][Full Text] [Related]
9. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.
Pincus SH; Cole RL; Hersh EM; Lake D; Masuho Y; Durda PJ; McClure J
J Immunol; 1991 Jun; 146(12):4315-24. PubMed ID: 1710247
[TBL] [Abstract][Full Text] [Related]
10. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.
Dadachova E; Patel MC; Toussi S; Apostolidis C; Morgenstern A; Brechbiel MW; Gorny MK; Zolla-Pazner S; Casadevall A; Goldstein H
PLoS Med; 2006 Nov; 3(11):e427. PubMed ID: 17090209
[TBL] [Abstract][Full Text] [Related]
11. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells.
Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG
Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567
[TBL] [Abstract][Full Text] [Related]
12. Passive immunization for the prevention and treatment of HIV infection.
Zolla-Pazner S; Gorny MK
AIDS; 1992 Nov; 6(11):1235-47. PubMed ID: 1472330
[No Abstract] [Full Text] [Related]
13. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
McCaffrey RA; Saunders C; Hensel M; Stamatatos L
J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
[TBL] [Abstract][Full Text] [Related]
14. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
15. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M
J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162
[TBL] [Abstract][Full Text] [Related]
16. Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.
Pincus SH; Song K; Maresh GA; Frank A; Worthylake D; Chung HK; Polacino P; Hamer DH; Coyne CP; Rosenblum MG; Marks JW; Chen G; Weiss D; Ghetie V; Vitetta ES; Robinson JE; Hu SL
J Virol; 2017 Feb; 91(3):. PubMed ID: 27795412
[TBL] [Abstract][Full Text] [Related]
17. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.
Cavacini LA; Emes CL; Wisnewski AV; Power J; Lewis G; Montefiori D; Posner MR
AIDS Res Hum Retroviruses; 1998 Sep; 14(14):1271-80. PubMed ID: 9764911
[TBL] [Abstract][Full Text] [Related]
18. [Human monoclonal antibodies to HIV-1 infection].
Kawai M; Okada N
Nihon Rinsho; 2002 Mar; 60(3):570-7. PubMed ID: 11904975
[TBL] [Abstract][Full Text] [Related]
19. In vivo testing of anti-HIV immunotoxins.
Pincus SH; Marcotte TK; Forsyth BM; Fang H
Methods Mol Biol; 2001; 166():277-94. PubMed ID: 11217373
[No Abstract] [Full Text] [Related]
20. Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner.
Musich T; Li L; Liu L; Zolla-Pazner S; Robert-Guroff M; Gorny MK
J Virol; 2017 Apr; 91(8):. PubMed ID: 28122974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
